Experts discuss evolving treatment strategies for metastatic castration-resistant prostate cancer, emphasizing personalized therapy and innovative options.

One of the most notable changes is a new thematic structure within urologic oncology. In this video, Bruno Nahar, MD, an associate professor of urologic oncology and the Eric and Elizabeth Feder ...

The Genomic Prostate Score (GPS) is being validated in the ProtecT trial to predict prostate cancer progression and treatment outcomes. ProtecT is a landmark phase 3 trial with over 1600 men, ...

PANVAC addition to BCG therapy did not improve recurrence-free survival in high-grade NMIBC patients compared to BCG alone. No significant differences were observed in secondary endpoints, including ...

ORIC-944 demonstrated significant anti-tumor activity and tolerability in combination with ARPIs in mCRPC patients. The phase 1b trial showed notable PSA and ctDNA reductions across all ORIC-944 dose ...

The Avvio ELS has received FDA breakthrough device designation, enhancing its development and review process for treating ureteral stones. The system uses microbubble-enhanced acoustic cavitation ...

Hear from 5 experts as they recap some of the top data from this year's ESMO Congress. Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates ...

Discover innovative approaches to treating premature ejaculation with insights from leading experts in sexual health and urology. At the 2025 Sexual Medicine Society of North America meeting in ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

Technological advancements in sacral neuromodulation include MRI-conditional devices, rechargeable systems, and extended battery lifespans, enhancing patient eligibility and reducing procedural ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

The TRAVERSE trial showed testosterone therapy's MACE risk is non-inferior to placebo, reassuring prescribers and patients. Despite the updated labeling, caution is advised due to potential venous ...